Filing Details
- Accession Number:
- 0001384101-19-000024
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-04 19:05:39
- Reporting Period:
- 2019-02-28
- Accepted Time:
- 2019-03-04 19:05:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1384101 | Veracyte Inc. | VCYT | Services-Medical Laboratories (8071) | 205455398 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1769333 | C Giulia Kennedy | 6000 Shoreline Court Suite 300 South San Francisco CA 94080 | Chief Scientific & Med Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-28 | 8,000 | $0.00 | 17,400 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2019-02-28 | 32,000 | $0.00 | 49,400 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2019-02-28 | 397 | $10.45 | 49,797 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-28 | 11,667 | $8.86 | 61,464 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-28 | 8,749 | $6.45 | 70,213 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-28 | 4,166 | $5.43 | 74,379 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-28 | 12,396 | $9.05 | 86,775 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-28 | 36,075 | $20.42 | 50,700 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-28 | 1,300 | $21.28 | 49,400 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-28 | 813 | $0.00 | 48,587 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2019-02-28 | 60,000 | $0.00 | 60,000 | $20.21 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-28 | 397 | $0.00 | 397 | $10.45 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-28 | 11,667 | $0.00 | 11,667 | $8.86 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-28 | 8,749 | $0.00 | 8,749 | $6.45 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-28 | 4,166 | $0.00 | 4,166 | $5.43 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-28 | 12,396 | $0.00 | 12,396 | $9.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 60,000 | 2029-02-27 | No | 4 | A | Direct | |
| 12,885 | 2024-09-15 | No | 4 | M | Direct | |
| 1,667 | 2025-03-01 | No | 4 | M | Direct | |
| 16,253 | 2026-02-28 | No | 4 | M | Direct | |
| 6,773 | 2026-03-14 | No | 4 | M | Direct | |
| 44,271 | 2027-03-02 | No | 4 | M | Direct |
Footnotes
- Restricted stock units awarded on February 28, 2019 vest 25% on March 2, 2020 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
- Restricted stock units awarded on February 28, 2019 vest 25% on February 28, 2021 and 75% on February 28, 2022 subject to continuing employment of the Reporting Person on each vesting date.
- Represents weighted average sales price. Sale prices for the transactions range from $20.11 to $21.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- Represents weighted average sales price. Sale prices for the transactions range from $21.14 to $21.39. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- The reporting person is reporting the withholding of 813 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,350 Restricted Stock Units granted on March 2, 2018. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4.
- The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- The option is fully vested and fully exercisable.
- The option becomes exercisable as to 25% of the shares on March 2, 2016, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- The option becomes exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
Billionaire Hedge Funds
